MZMaryam Zare

Maryam Zare

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Maryam Zare has a total of 21 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Effects of Bread Fortification With Pomegranate Peel Powder on Inflammation Biomarkers, Oxidative Stress, and Mood Status in Patients With Type 2 Diabetes: A Randomized Placebo‐Controlled Trial

    by Maryam Zare, Mohammad Javad Tarrahi, Omid Sadeghi, Mozhgan Karimifar, Sayed Amir Hossein Goli, Reza Amani

    We hypothesized that bread fortified with pomegranate peel powder (PPP) would improve inflammation, oxidative stress, and mood in patients with type 2 diabetes mellitus (T2DM). To confirm this, its effect on the parameters above was evaluated. In total, 90 T2DM patients were randomized to receive either bread fortified with 3.5% PPP ( N = 45) or PPP‐free bread for 12 weeks ( N = 45). Dietary intake throughout the trial was assessed via food records. Laboratory parameters, including total antioxidant capacity (TAC), malondialdehyde (MDA), high‐sensitivity C‐reactive protein (hs‐CRP), and psychological disorders, including depression, anxiety, and stress, were assessed at the beginning and end of the study. 77 diabetic patients completed the trial (PPP group = 39 and control group = 38). Based on the compliance assessment, adherence to the interventions was high in the trial. We detected significant reductions in hs‐CRP levels (intervention group: change = −0.56 ± 1.29, p = 0.01; control group: change = −0.81 ± 1.16, p < 0.001) and depression scores (intervention group: change = −1.33 ± 3.66, p = 0.04; control group: change = −1.44 ± 2.83, p = 0.01). There was no significant difference between the groups. After adjusting for confounding factors, the important effect within the group disappeared. Other variables, including MDA, TAC, anxiety, and stress, did not significantly change in the two study groups. Whereas 12 weeks of consumption of PPP‐fortified bread failed to significantly affect oxidative stress, hs‐CRP levels, or mental state in T2DM patients, partial beneficial effects on inflammation and mood suggest the need for further research.


  • Effects of pomegranate peel powder-fortified bread consumption in patients with type 2 diabetes mellitus: randomized controlled trial

    by Maryam Zare, Atefe Rezaei, Mozhgan Karimifar, Mohammad Javad Tarrahi, Sahar Saraf-Bank, Sayed Amir Hossein Goli, Reza Amani

    Objectives Type 2 diabetes mellitus (T2DM) poses a huge global disease burden due to high morbidity and mortality rates. Dietary modifications can significantly regulate T2DM risk factors. This study primarily aimed to investigate the effects of bread fortified with pomegranate peel powder (PPP) on glycemic control, lipid profile, and anthropometric measures in patients with T2DM. Methods PPP was added to bread by adding 0, 1.5, 2.5, 3.5, and 5% PPP. We measured the phenol content by Folin-Ciocalteu and the antioxidant activity via DPPH (2,2-diphenyl-1-picrylhydrazyl). Ninety participants were then allocated to a randomized parallel controlled intervention study, and the effects of consuming 100 g/day of bread with PPP (3.5%) on glycemic markers, lipid profiles, and anthropometrics were assessed. The bread administered to the control group was the same as that used for the intervention group except for the absence of PPP. Results The PPP-fortified bread contained greater polyphenol levels and antioxidant activity than the bread without PPP. Compared to the control bread, fortified bread with PPP showed no significant effects on anthropometric measures, blood pressure, glycemic levels, and lipid markers after adjusting for age, sex, and caloric intake. Conclusions In comparison with control bread, PPP bread does not show much effect on glycemic parameters, lipid profile, and anthropometric measurements. Extended duration, different doses, and larger sample sizes are advisable for further studies. Trial registration IRCT20191209045672N1 is the trial ID in the Iranian Registry of Clinical Trials. Date of registration 21/09/2020. https//en.irct.ir/trial/48,132.


  • Open Access

    Association of retinol-binding protein 4 with metabolic syndrome in first-degree relatives of type 2 diabetic patients

    by Marjan Tabesh, Atsa Noroozi, Masood Amini, Awat Feizi, Sahar Saraf-Bank, Maryam Zare

    Background: Retinol-binding protein 4 (RBP4) is known to regulate lipid and glucose metabolism and insulin resistance. The influences of RBP4 on metabolic syndrome (MS) are still unclear. The purpose of this study is to evaluate the association between serum levels of RBP4 and MS components in first-degree relations of type 2 diabetic patients. Materials and Methods: This cross-sectional study was performed within the framework of the diabetes prevention project in Isfahan. This study has been conducted during 2012–2013. Seventy-eight subjects participate, with an average age of 43.20 ± 5.29 years. Weight, height, waist and hip circumferences, blood pressure (BP) of participants, fasting plasma glucose, hemoglobin A1c, total cholesterol, high-density lipoprotein cholesterol, triglyceride (TG), and serum RBP4 were measured from fasting blood sample taken from each participant after an overnight fast (12–14 h). Results: Systolic and diastolic BP were significantly higher in people in top median of RBP4 (11.8 ± 1.5 vs. 11.0 ± 1.2, P = 0.01 and 7.8 ± 1.0 vs. 7.3 ± 0.9, P = 0.03). Moreover, TG in people with high levels of RBP4 was higher compared with those with low levels of RBP4 (177.7 ± 97.6 vs. 138.7 ± 56.9, P = 0.02). People with low levels of RBP4 had significant greater hip circumferences (107.9 ± 7.5 vs. 104.3 ± 8.0, P = 0.04). There was no correlation between RBP4 and MS in crude model (odds ratio [OR]: 1.00, 0.95–1.05, P = 0.97). This null correlation remained after adjustment for body mass index, age, and physical activity (OR: 0.93, 0.91–1.07, P = 0.31). Conclusion: Although RBP4 levels were positively association with some risk factors of MS including hip circumference, TG, and systolic and diastolic BP, it does not seem to be a valuable marker for identification of the MS in the first relative degree of diabetic patients.


  • Open Access

    Effects of Concentrated Pomegranate Juice on Subclinical Inflammation and Cardiometabolic Risk Factors for Type 2 Diabetes: A Quasi-Experimental Study

    by Farideh Shishehbor, Majid Mohammad Shahi, Mehdi Zarei, Azadeh Saki, Mehrnoosh Zakerkish, Fatemeh Shirani, Maryam Zare

    Background: The health benefits of pomegranate juice have been reported in several studies. However, limited clinical trials have examined the effects of concentrated pomegranate juice (CPJ) on inflammatory factors. Objectives: This study aimed to investigate the effects of CPJ on metabolic risk factors, including inflammatory biomarkers, in patients with type 2 diabetes mellitus. Patients and Methods: In a quasi-experiment trial, 40 type 2 diabetic patients were asked to consume 50 g of CPJ daily for 4 weeks. Anthropometric indices, dietary intake, blood pressure measurements, and fasting blood samples were conducted at baseline and 4 weeks after the intervention. Results: The intake of CPJ produced a significant increase in both total and high-density lipoprotein cholesterol (HDL-C) (4.7% and 3.9%, respectively) from baseline (P < 0.05). However, changes that were observed in serum triglyceride (TG), low-density lipoprotein cholesterol (LDL-C), fasting blood glucose, and blood pressure were not statistically significant. Administration of CPJ caused significant reduction in serum interleukin-6 (IL-6) (P < 0.05), but tumor necrosis factor-α (TNF-α) and high-sensitivity C-reactive protein (hs-CRP) remained unchanged during the study. The mean value of serum total antioxidant capacity (TAC) was substantially increased (~ 75%) from 381.88 ± 114.4 at baseline to 1501 ± 817 after 4 weeks of CPJ consumption. Conclusions: Consumption of CPJ (50 g/day) appears to have favorable effects on some markers of subclinical inflammation, and to increase plasma concentrations of antioxidants in patients with type 2 diabetes. Keywords: Concentrated Pomegranate Juice; TNF-α; IL-6; TAC; LDL-C; HDL-C; type 2 Diabetes; hs-CRP